drugset / Trial / NCT03252600
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Phase 2
Unknown
53 enrolled
Barbara Ann Karmanos Cancer Institute
Bristol-Myers Squibb · collabMultiple Myeloma Research Consortium · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase II trial studies how well lenalidomide, dexamethasone, and eotuzumab with or without cyclophosphamide work in treating patients with primary amyloidosis that has come back after a period of improvement. Drugs used in chemotherapy, such as lenalidomide, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as eotuzumab, may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide, dexamethasone, and eotuzumab with cyclophosphamide may work better in treating patients with primary amyloidosis.
Timeline
- Start
- 2017-08-25
- Primary completion
- 2023-12-07
- Completion
- 2023-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Dexamethasone | Small molecule | — | Intravenous |
| Subject | Elotuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |